Loading...
XNAS
BLRX
Market cap873kUSD
Jul 09, Last price  
3.03USD
1D
0.66%
1Q
32.31%
Jan 2017
-99.45%
IPO
-99.90%
Name

BioLine RX Ltd

Chart & Performance

D1W1MN
XNAS:BLRX chart
P/E
—
P/S
11.09
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-24.60%
Rev. gr., 5y
%
Revenues
1m
-95.89%
016,271,95631,894,1140000000000004,800,00028,940,0001,189,360
Net income
-1m
L-87.16%
-32,059,866-15,663,1802,096,961-13,186,022-20,415,210-17,641,923-10,174,810-14,400,000-15,841,000-24,352,000-22,962,000-25,446,000-30,021,000-27,054,000-24,951,000-60,614,000-9,221,000-1,184,321
CFO
-8m
L-81.45%
-27,955,553-21,513,63911,463,110-11,222,017-20,114,081-20,233,740-14,479,715-14,168,000-14,513,000-20,547,000-24,192,000-22,666,000-23,206,000-23,573,000-26,240,000-22,608,000-43,873,000-8,138,050

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
URL
https://www.biolinerx.com/
IPO date
Jan 30, 2007
Employees
49
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT